• 1

    Jemal A, Siegel R, Ward E et al. . Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 3

    Gail MH, Costantino JP, Bryant J et al. . Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:18291846.

    • Search Google Scholar
    • Export Citation
  • 4

    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146151.

  • 5

    White J, Morrow M, Moughan J et al. . Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893904.

    • Search Google Scholar
    • Export Citation
  • 6

    Wilkinson NW, Shahryarinejad A, Winston JS et al. . Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:3843.

    • Search Google Scholar
    • Export Citation
  • 7

    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235237.

  • 8

    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678687.

  • 9

    Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159169; discussion 170, 173–154, 177.

    • Search Google Scholar
    • Export Citation
  • 10

    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:16011602.

  • 11

    Houssami N, Ciatto S, Macaskill P et al. . Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:32483258.

    • Search Google Scholar
    • Export Citation
  • 12

    Fischer U, Zachariae O, Baum F et al. . The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:17251731.

    • Search Google Scholar
    • Export Citation
  • 13

    Solin LJ, Orel SG, Hwang WT et al. . Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386391.

    • Search Google Scholar
    • Export Citation
  • 14

    Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April 30, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc1-14f.pdf. Accessed October 3, 2007.

    • Search Google Scholar
    • Export Citation
  • 15

    Puglisi F, Follador A, Minisini AM et al. . Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263266.

    • Search Google Scholar
    • Export Citation
  • 16

    Kumar R, Chauhan A, Zhuang H et al. . Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267274.

    • Search Google Scholar
    • Export Citation
  • 17

    Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277285.

    • Search Google Scholar
    • Export Citation
  • 18

    Podoloff DA, Advani RH, Allred C et al. . NCCN Task Force Report: PET/CT scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S124.

  • 19

    Carr CE, Conant EF, Rosen MA et al. . The impact of FDG PET in the staging of breast cancer [abstract]. J Clin Oncol 2006:24:18 (Suppl 1):Abstract 530.

    • Search Google Scholar
    • Export Citation
  • 20

    Khan QJ, O’Dea AP, Dusing R et al. . Integrated FDG-PET for initial staging of breast cancer [abstract]. J Clin Oncol 2007;25:18(Suppl 1):Abstract 558.

    • Search Google Scholar
    • Export Citation
  • 21

    Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. RadiGraphics 2007;27:S215229.

  • 22

    Wang S, Saboorian MH, Frenkel E et al. . Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374381.

    • Search Google Scholar
    • Export Citation
  • 23

    DAKO HercepTest [package insert]. Carpinteria, CA: DAKO Corp; 2004.

  • 24

    Pathway HER2 [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2004.

  • 25

    INFORM HER2/neu gene detection system [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2001.

  • 26

    PathVysion HER2/neu method [package insert]. Downers Grove, IL: Vysis, Inc.; 2001.

  • 27

    SPOT-Light HER2 CISH kit [package insert]. Camarillo, CA: Invitrogen Corp.; 2008.

  • 28

    Anderson S, Gilkerson E, Klein P. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat 2002;76:S68:Abstract 235.

    • Search Google Scholar
    • Export Citation
  • 29

    Paik S, Bryant J, Tan-Chiu E et al. . Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852854.

    • Search Google Scholar
    • Export Citation
  • 30

    Paik S, Tan-Chiu E, Bryant J et al. . Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat 2002;76(Suppl):S31.

    • Search Google Scholar
    • Export Citation
  • 31

    Perez EA, Suman VJ, Davidson NE et al. . HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:30323038.

    • Search Google Scholar
    • Export Citation
  • 32

    Tubbs RR, Pettay JD, Roche PC et al. . Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:27142721.

    • Search Google Scholar
    • Export Citation
  • 33

    Press MF, Sauter G, Bernstein L et al. . Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:65986607.

    • Search Google Scholar
    • Export Citation
  • 34

    Carlson RW, Moench SJ, Hammond MEH et al. . HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S122.

    • Search Google Scholar
    • Export Citation
  • 35

    Wolff AC, Hammond ME, Schwartz JN et al. . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118147.

    • Search Google Scholar
    • Export Citation
  • 36

    Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):S2328.

  • 37

    Paik S, Bryant J, Park C et al. . ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:13611370.

    • Search Google Scholar
    • Export Citation
  • 38

    Paik S, Bryant J, Tan-Chiu E et al. . HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:19911998.

    • Search Google Scholar
    • Export Citation
  • 39

    Piccart MJ, Di Leo A, Hamilton A. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:17551761.

    • Search Google Scholar
    • Export Citation
  • 40

    Thor AD, Berry DA, Budman DR et al. . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:13461360.

    • Search Google Scholar
    • Export Citation
  • 41

    Pritchard KI, Shepherd LE, O’Malley FP et al. . HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:21032111.

    • Search Google Scholar
    • Export Citation
  • 42

    Dressler LG, Berry DA, Broadwater G et al. . Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:42874297.

    • Search Google Scholar
    • Export Citation
  • 43

    Romond EH, Perez EA, Bryant J et al. . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 44

    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 45

    Slamon D, Eiermann W, Robert N et al. . Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.

    • Search Google Scholar
    • Export Citation
  • 46

    Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. . Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 47

    Cobleigh MA, Vogel CL, Tripathy D et al. . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:26392648.

    • Search Google Scholar
    • Export Citation
  • 48

    Slamon DJ, Leyland-Jones B, Shak S et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 49

    Vogel CL, Cobleigh MA, Tripathy D et al. . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719726.

    • Search Google Scholar
    • Export Citation
  • 50

    Allred DC, Harvey JM, Berardo M et al. . Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1999;11:155168.

    • Search Google Scholar
    • Export Citation
  • 51

    Rhodes A, Jasani B, Barnes DM et al. . Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125130.

    • Search Google Scholar
    • Export Citation
  • 52

    Rudiger T, Höfler H, Kreipe HH et al. . Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873882.

    • Search Google Scholar
    • Export Citation
  • 53

    Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:15581564.

    • Search Google Scholar
    • Export Citation
  • 54

    Clarke M, Collins R, Darby S et al. . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:20872106.

    • Search Google Scholar
    • Export Citation
  • 55

    Fisher B, Anderson S, Bryant J et al. . Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:12331241.

    • Search Google Scholar
    • Export Citation
  • 56

    Veronesi U, Cascinelli N, Mariani L et al. . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:12271232.

    • Search Google Scholar
    • Export Citation
  • 57

    McCormick B. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301307.

    • Search Google Scholar
    • Export Citation
  • 58

    Pignol J-P, Olivotto E, Rakovitch WE et al. . Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol 2006;66:S1.

    • Search Google Scholar
    • Export Citation
  • 59

    Whelan T, MacKenzie R, Julian J et al. . Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:11431150.

    • Search Google Scholar
    • Export Citation
  • 60

    Antonini N, Jones H, Horiot JC et al. . Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol 2007;82:265271.

    • Search Google Scholar
    • Export Citation
  • 61

    Bartelink H, Horiot JC, Poortmans P et al. . Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:13781387.

    • Search Google Scholar
    • Export Citation
  • 62

    Jones H, Antonini N, Colette L et al. . The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys 2007;69(3 Suppl):S23.

    • Search Google Scholar
    • Export Citation
  • 63

    Fourquet A, Campana F, Zafrani B et al. . Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719725.

    • Search Google Scholar
    • Export Citation
  • 64

    Komoike Y, Akiyama F, Iino Y et al. . Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:3541.

    • Search Google Scholar
    • Export Citation
  • 65

    Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:5157.

    • Search Google Scholar
    • Export Citation
  • 66

    Golshan M, Miron A, Nixon AJ et al. . The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:5862.

    • Search Google Scholar
    • Export Citation
  • 67

    Kroman N, Holtveg H, Wohlfahrt J et al. . Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688693.

    • Search Google Scholar
    • Export Citation
  • 68

    Hughes KS, Schnaper LA, Berry D et al. . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971977.

    • Search Google Scholar
    • Export Citation
  • 69

    Hughes KS, Schnaper LA, Berry D et al. . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.

    • Search Google Scholar
    • Export Citation
  • 70

    Fyles AW, McCready DR, Manchul LA et al. . Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963970.

    • Search Google Scholar
    • Export Citation
  • 71

    Recht A, Come SE, Henderson IC et al. . The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:13561361.

    • Search Google Scholar
    • Export Citation
  • 72

    Dubey A, Recht A, Come SE et al. . Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999;45:877884.

    • Search Google Scholar
    • Export Citation
  • 73

    Markiewicz DA, Schultz DJ, Haas JA et al. . The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996;35:661668.

    • Search Google Scholar
    • Export Citation
  • 74

    Abner AL, Recht A, Vicini FA et al. . Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1991;21:331338.

    • Search Google Scholar
    • Export Citation
  • 75

    Lyman GH, Giuliano AE, Somerfield MR et al. . American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:77037720.

    • Search Google Scholar
    • Export Citation
  • 76

    Bass SS, Lyman GH, McCann CR et al. . Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288295.

  • 77

    Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8(9 Suppl):67S70S.

  • 78

    Cox CE, Nguyen K, Gray RJ et al. . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513519; discussion 519–521.

    • Search Google Scholar
    • Export Citation
  • 79

    Krag D, Weaver D, Ashikaga T et al. . The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941946.

  • 80

    McMasters KM, Giuliano AE, Ross MI et al. . Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998;339:990995.

    • Search Google Scholar
    • Export Citation
  • 81

    O’Hea BJ, Hill AD, El-Shirbiny AM et al. . Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423427.

    • Search Google Scholar
    • Export Citation
  • 82

    Veronesi U, Paganelli G, Viale G et al. . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546553.

    • Search Google Scholar
    • Export Citation
  • 83

    Kuehn T, Vogl FD, Helms G et al. . Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252259.

    • Search Google Scholar
    • Export Citation
  • 84

    Mansel RE, Fallowfield L, Kissin M et al. . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599609.

    • Search Google Scholar
    • Export Citation
  • 85

    Dupont E, Cox C, Shivers S et al. . Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:9296.

  • 86

    Cox CE, Salud CJ, Cantor A et al. . Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593600.

    • Search Google Scholar
    • Export Citation
  • 87

    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:14151418.

    • Search Google Scholar
    • Export Citation
  • 88

    Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:24962501.

    • Search Google Scholar
    • Export Citation
  • 89

    Fisher B, Redmond C, Fisher ER et al. . Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674681.

    • Search Google Scholar
    • Export Citation
  • 90

    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients. Cancer 2008;114:8993.

    • Search Google Scholar
    • Export Citation
  • 91

    Fisher B, Bryant J, Wolmark N et al. . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:26722685.

    • Search Google Scholar
    • Export Citation
  • 92

    Bear HD, Anderson S, Smith RE et al. . Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol 2006;24:20192027.

    • Search Google Scholar
    • Export Citation
  • 93

    Buzdar AU, Ibrahim NK, Francis D et al. . Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:36763685.

    • Search Google Scholar
    • Export Citation
  • 94

    Smith IE, Dowsett M, Ebbs SR et al. . Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:51085116.

    • Search Google Scholar
    • Export Citation
  • 95

    Ellis MJ, Coop A, Singh B et al. . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:38083816.

    • Search Google Scholar
    • Export Citation
  • 96

    Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996997.

  • 97

    Overgaard M, Jensen MB, Overgaard J et al. . Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:16411648.

    • Search Google Scholar
    • Export Citation
  • 98

    Ragaz J, Olivotto IA, Spinelli JJ et al. . Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116126.

    • Search Google Scholar
    • Export Citation
  • 99

    Overgaard M, Hansen PS, Overgaard J et al. . Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949955.

    • Search Google Scholar
    • Export Citation
  • 100

    Recht A, Edge SB, Solin LJ et al. . Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:15391569.

    • Search Google Scholar
    • Export Citation
  • 101

    Theriault R, Buzdar A, Hortobagyi G et al. . Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol 1998;17:99a. Abstract 381.

    • Search Google Scholar
    • Export Citation
  • 102

    McGuire SE, Gonzolez-Angulo AM, Huang EH et al. . Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:10041009.

    • Search Google Scholar
    • Export Citation
  • 103

    Huang EH, Tucker SL, Strom EA et al. . Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:46914699.

    • Search Google Scholar
    • Export Citation
  • 104

    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247253.

    • Search Google Scholar
    • Export Citation
  • 105

    Nielsen HM, Overgaard M, Grau C et al. . Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:22682275.

    • Search Google Scholar
    • Export Citation
  • 106

    Anderson BO, Masetti R, Silverstein MJ, Oncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol 2005;6:145157.

    • Search Google Scholar
    • Export Citation
  • 107

    Huemer GM, Schrenk P, Moser F et al. . Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390398.

    • Search Google Scholar
    • Export Citation
  • 108

    Malycha PL, Gough IR, Margaritoni M et al. . Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg 2008;32:25702577.

    • Search Google Scholar
    • Export Citation
  • 109

    Kaur N, Petit JY et al. . Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539545.

    • Search Google Scholar
    • Export Citation
  • 110

    Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972979.

  • 111

    Ravdin PM, Siminoff LA, Davis GJ et al. . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980991.

    • Search Google Scholar
    • Export Citation
  • 112

    Olivotto IA, Bajdik CD, Ravdin PM et al. . Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:27162725.

    • Search Google Scholar
    • Export Citation
  • 113

    Loprinzi CL, Ravdin PM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189198.

    • Search Google Scholar
    • Export Citation
  • 114

    Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291300.

    • Search Google Scholar
    • Export Citation
  • 115

    Sorlie T, Perou CM, Tibshirani R et al. . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:1086910874.

    • Search Google Scholar
    • Export Citation
  • 116

    Perou CM, Jeffrey SS, van de Rijn M et al. . Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:92129217.

    • Search Google Scholar
    • Export Citation
  • 117

    Sorlie T, Tibshirani R, Parker J et al. . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:84188423.

    • Search Google Scholar
    • Export Citation
  • 118

    Wang Y, Klijn JG, Zhang Y et al. . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671679.

    • Search Google Scholar
    • Export Citation
  • 119

    van ‘t Veer LJ, Dai H, van de Vijver MJ et al. . Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530536.

  • 120

    van der Vijver MJ, He YD, van’t Veer LJ et al. . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:19992009.

    • Search Google Scholar
    • Export Citation
  • 121

    Glas AM, Floore A, Delahaye LJ et al. . Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278287.

    • Search Google Scholar
    • Export Citation
  • 122

    Paik S, Shak S, Tang G et al. . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:28172826.

    • Search Google Scholar
    • Export Citation
  • 123

    Paik S, Tang G, Shak S et al. . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:37263734.

    • Search Google Scholar
    • Export Citation
  • 124

    Fan C, Oh DS, Wessels L et al. . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560569.

  • 125

    Swain SM, Wilson JW, Mamounas EP et al. . Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516523.

    • Search Google Scholar
    • Export Citation
  • 126

    Berry D, Cirrincione C, Henderson IC et al. . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:16581667.

    • Search Google Scholar
    • Export Citation
  • 127

    Albain K, Barlow W, O’Malley F et al. . Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.

    • Search Google Scholar
    • Export Citation
  • 128

    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 129

    Berry DA, Muss HB, Thor AD et al. . HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:34713479.

    • Search Google Scholar
    • Export Citation
  • 130

    Eppenberger-Castori S, Kueng W, Benz C et al. . Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645656.

    • Search Google Scholar
    • Export Citation
  • 131

    Knoop AS, Bentzen SM, Nielsen MM et al. . Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:33763384.

    • Search Google Scholar
    • Export Citation
  • 132

    Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(Suppl):4652; discussion 92–100.

    • Search Google Scholar
    • Export Citation
  • 133

    Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:6577.

    • Search Google Scholar
    • Export Citation
  • 134

    De Laurentiis M, Arpino G, Massarelli E et al. . A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 135

    Paik S, Shak S, Tang G et al. . Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23:16(Suppl 1): Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 136

    Arpino G, Green SJ, Allred DC et al. . HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:56705676.

    • Search Google Scholar
    • Export Citation
  • 137

    Dowsett M, Allred C, Knox J et al. . Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:10591065.

    • Search Google Scholar
    • Export Citation
  • 138

    Coombes RC, Kilburn LS, Snowdon CF et al. . Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:559570.

    • Search Google Scholar
    • Export Citation
  • 139

    Kaufmann M, Jonat W, Hilfrich J et al. . Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007;25:26642670.

    • Search Google Scholar
    • Export Citation
  • 140

    Goss PE, Ingle JN, Martino S et al. . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:12621271.

    • Search Google Scholar
    • Export Citation
  • 141

    Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:4553.

    • Search Google Scholar
    • Export Citation
  • 142

    Thurlimann B, Keshaviah A, Coates AS et al. . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 143

    Baum M, Budzar AU, Cuzick J et al. . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 144

    Howell A, Cuzick J, Baum M et al. . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 145

    Duffy S, Jackson TL, Lansdown M et al. . The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545553.

    • Search Google Scholar
    • Export Citation
  • 146

    Fallowfield L, Cella D, Cuzick J et al. . Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:42614271.

    • Search Google Scholar
    • Export Citation
  • 147

    Eastell R, Adams JE, Coleman RE et al. . Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:10511057.

    • Search Google Scholar
    • Export Citation
  • 148

    Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317324.

    • Search Google Scholar
    • Export Citation
  • 149

    Buzdar AU, Guastalla JP, Nabholtz JM et al. . Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006;107:472480.

    • Search Google Scholar
    • Export Citation
  • 150

    Mouridsen H, Keshaviah A, Coates AS et al. . Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol 2007;25:57155722.

    • Search Google Scholar
    • Export Citation
  • 151

    Boccardo F, Rubagotti A, Puntoni M et al. . Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:51385147.

    • Search Google Scholar
    • Export Citation
  • 152

    Boccardo F, Rubagotti A, Guglielmini P et al. . Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):vii1014.

    • Search Google Scholar
    • Export Citation
  • 153

    Coombes RC, Hall E, Gibson LJ et al. . A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 154

    Jakesz R, Jonat W, Gnant M et al. . Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455462.

    • Search Google Scholar
    • Export Citation
  • 155

    Jonat W, Gnant M, boccardo F et al. . Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991996.

    • Search Google Scholar
    • Export Citation
  • 156

    Goss PE, Ingle JN, Martino S et al. . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 157

    Goss PE, PE, Ingle JN, Pater JL et al. . Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:19481955.

    • Search Google Scholar
    • Export Citation
  • 158

    Whelan TJ, Goss PE, Ingle JN et al. . Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:69316940.

    • Search Google Scholar
    • Export Citation
  • 159

    Perez EA, Josse RG, Pritchard KI et al. . Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:36293635.

    • Search Google Scholar
    • Export Citation
  • 160

    Braverman AS, Sawhney H, Tendler A et al. . Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 164.

    • Search Google Scholar
    • Export Citation
  • 161

    Smith IE, Dowsett M, Yap YS et al. . Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:24442447.

    • Search Google Scholar
    • Export Citation
  • 162

    Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst 2006;98:10961097.

  • 163

    Early Breast Cancer Trialists’ Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930942

    • Search Google Scholar
    • Export Citation
  • 164

    Wood WC, Budman DR, Korzun AH et al. . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:12531259.

    • Search Google Scholar
    • Export Citation
  • 165

    Menard S, Valagussa P, Pilotti S et al. . Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329335.

    • Search Google Scholar
    • Export Citation
  • 166

    Muss HB, Thor AD, Berry DA et al. . c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:12601266.

    • Search Google Scholar
    • Export Citation
  • 167

    Bang SM, Heo DS, Lee KH et al. . Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:25212526.

    • Search Google Scholar
    • Export Citation
  • 168

    Fisher B, Anderson S, Tan-Chiu E et al. . Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931942.

    • Search Google Scholar
    • Export Citation
  • 169

    Fisher B, Brown AM, Dimitrov NV et al. . Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:14831496.

    • Search Google Scholar
    • Export Citation
  • 170

    Fisher B, Anderson S, Wickerham DL et al. . Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:18581869.

    • Search Google Scholar
    • Export Citation
  • 171

    Henderson IC, Berry DA, Demetri GD et al. . Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976983.

    • Search Google Scholar
    • Export Citation
  • 172

    Mamounas EP, Bryant J, Lembersky B et al. . Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:36863696.

    • Search Google Scholar
    • Export Citation
  • 173

    Citron ML, Berry DA, Cirrincione C et al. . Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 174

    Levine MN, Pritchard KI, Bramwell VH et al. . Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:51665170.

    • Search Google Scholar
    • Export Citation
  • 175

    French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602611.

    • Search Google Scholar
    • Export Citation
  • 176

    Piccart MJ, Di Leo A, Beauduin M et al. . Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:31033110.

    • Search Google Scholar
    • Export Citation
  • 177

    Roche H, Fumoleau P, Spielmann M et al. . Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:56645671.

    • Search Google Scholar
    • Export Citation
  • 178

    Martin M, Pienkowski T, Mackey J et al. . Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:23022313.

  • 179

    Sparano JA, Wang M, Martino S et al. . Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:16631671.

  • 180

    Sparano JA, Wang M, Martino S et al. . Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.

    • Search Google Scholar
    • Export Citation
  • 181

    Jones S, Holmes F, O’Shaughnessey J et al. . Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.

    • Search Google Scholar
    • Export Citation
  • 182

    Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:16521654.

  • 183

    Perez EA, Romond EH, Suman VJ et al. . Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 512.

    • Search Google Scholar
    • Export Citation
  • 184

    Tan-Chiu E, Yothers G, Romond E et al. . Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 185

    Perez EA, Suman VJ, Davidson NE et al. . Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:12311238.

    • Search Google Scholar
    • Export Citation
  • 186

    Geyer CE, Bryant JL, Romond MS et al. . Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol 2006;24(Suppl 1):Abstract 581.

    • Search Google Scholar
    • Export Citation
  • 187

    Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:35253533.

    • Search Google Scholar
    • Export Citation
  • 188

    Smith I, Procter M, Gelber RD et al. . 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007:369:2936.

    • Search Google Scholar
    • Export Citation
  • 189

    Norris B, Chia S, Cheang M et al. . Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.

    • Search Google Scholar
    • Export Citation
  • 190

    Untch M, Gelber RD, Jackisch C et al. . Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:10901096.

    • Search Google Scholar
    • Export Citation
  • 191

    Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.

    • Search Google Scholar
    • Export Citation
  • 192

    Rosselli Del Turco M, Palli D, Cariddi A et al. . Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA 1994;271:15931597.

    • Search Google Scholar
    • Export Citation
  • 193

    Smith TJ, Davidson NE, Schapira DV et al. . American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:10801082.

    • Search Google Scholar
    • Export Citation
  • 194

    The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:15871592.

    • Search Google Scholar
    • Export Citation
  • 195

    Bast RC Jr, Ravdin P, Hayes DF et al. . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:18651878.

    • Search Google Scholar
    • Export Citation
  • 196

    Kirova YM, Stoppa-Lyonnet D, Savignoni A et al. . Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:23042311.

    • Search Google Scholar
    • Export Citation
  • 197

    Pierce LJ, Levin AM, Rebbeck TR et al. . Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:24372443.

    • Search Google Scholar
    • Export Citation
  • 198

    Metcalfe K, Lynch HT, Ghadirian P et al. . Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:23282335.

  • 199

    American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:14751478.

    • Search Google Scholar
    • Export Citation
  • 200

    Loprinzi CL, Kugler JW, Sloan JA et al. . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:20592063.

    • Search Google Scholar
    • Export Citation
  • 201

    Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412413.

  • 202

    Jin Y, Desta Z, Stearns V et al. . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:3039.

    • Search Google Scholar
    • Export Citation
  • 203

    Hillner BE, Ingle JN, Chlebowski RT et al. . American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:40424057.

    • Search Google Scholar
    • Export Citation
  • 204

    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487497.

  • 205

    Eubank WB, Mankoff D, Bhattacharya M et al. . Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479486.

    • Search Google Scholar
    • Export Citation
  • 206

    Moon DH, Maddahi J, Silverman DH et al. . Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431435.

    • Search Google Scholar
    • Export Citation
  • 207

    Vernon CC, Hand JW, Field SB et al. . Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731744.

    • Search Google Scholar
    • Export Citation
  • 208

    Jones EL, Oleson JR, Prosnitz LR et al. . Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:30793085.

  • 209

    Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology 2008;22:614623; discussion 623, 627–629.

    • Search Google Scholar
    • Export Citation
  • 210

    Theriault RL, Biermann JS, Brown E et al. . NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw 2006;(4 Suppl 2):S120.

  • 211

    Conte PF, Latreille J, Mauriac L et al. . Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:25522559.

    • Search Google Scholar
    • Export Citation
  • 212

    Hortobagyi GN, Theriault RL, Lipton A et al. . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:20382044.

    • Search Google Scholar
    • Export Citation
  • 213

    Theriault RL, Lipton A, Hortobagyi GN et al. . Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846854.

    • Search Google Scholar
    • Export Citation
  • 214

    Berenson JR, Rosen LS, Howell A et al. . Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:11911200.

    • Search Google Scholar
    • Export Citation
  • 215

    Ali SM, Esteva FJ, Hortobagyi G et al. . Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:34343437.

  • 216

    Theriault RL. The role of bisphosphonates in breast cancer. J Natl Compr Canc Netw 2003;1:232241.

  • 217

    Rosen LS, Gordon D, Kaminski M et al. . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377387.

    • Search Google Scholar
    • Export Citation
  • 218

    Rosen LS, Gordon DH, Dugan W Jr et al. . Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:3643.

    • Search Google Scholar
    • Export Citation
  • 219

    Lipton A, Theriault RL, Hortobagyi GN et al. . Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:10821090.

    • Search Google Scholar
    • Export Citation
  • 220

    Hortobagyi GN, Theriault RL, Porter L et al. . Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:17851971.

    • Search Google Scholar
    • Export Citation
  • 221

    Diel IJ, Body JJ, Lichinitser MR et al. . Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:17041712.

    • Search Google Scholar
    • Export Citation
  • 222

    McLachlan SA, Cameron D, Murray R et al. . Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:4348.

    • Search Google Scholar
    • Export Citation
  • 223

    Pecherstorfer M, Rivkin S, Body JJ et al. . Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315322.

    • Search Google Scholar
    • Export Citation
  • 224

    Lipton A, Theriault RL, Hortobagyi GN et al. . Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:10821090.

    • Search Google Scholar
    • Export Citation
  • 225

    Rosen LS, Gordon D, Kaminski M et al. . Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:17351744.

    • Search Google Scholar
    • Export Citation
  • 226

    Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:10161024.

    • Search Google Scholar
    • Export Citation
  • 227

    Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med 2006;144:753761.

    • Search Google Scholar
    • Export Citation
  • 228

    Buzdar A, Douma J, Davidson N et al. . Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:33573366.

    • Search Google Scholar
    • Export Citation
  • 229

    Buzdar AU, Jonat W, Howell A et al. . Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:11421152.

    • Search Google Scholar
    • Export Citation
  • 230

    Bonneterre J, Thurlimann B, Robertson JF et al. . Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:37483757.

    • Search Google Scholar
    • Export Citation
  • 231

    Nabholtz JM, Buzdar A, Pollak M et al. . Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:37583767.

    • Search Google Scholar
    • Export Citation
  • 232

    Vergote I, Bonneterre J, Thurlimann B et al. . Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000;36(Suppl 4):S8485.

    • Search Google Scholar
    • Export Citation
  • 233

    Paridaens R, Therasse P, Dirix L et al. . First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol 2004;22:14S (Suppl 1):Abstract 515.

    • Search Google Scholar
    • Export Citation
  • 234

    Klijn JG, Blamey RW, Boccardo F et al. . Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343353.

    • Search Google Scholar
    • Export Citation
  • 235

    Osborne CK, Pippen J, Jones SE et al. . Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:33863395.

    • Search Google Scholar
    • Export Citation
  • 236

    Howell A, Robertson JF, Quaresma Albano J et al. . Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:33963403.

    • Search Google Scholar
    • Export Citation
  • 237

    Robertson JF, Osborne CK, Howell A et al. . Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229238.

    • Search Google Scholar
    • Export Citation
  • 238

    Ingle JN, Suman VJ, Rowland KM et al. . Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:10521056.

    • Search Google Scholar
    • Export Citation
  • 239

    Chia S, Gradishar W, Mauriac L et al. . Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:16641670.

    • Search Google Scholar
    • Export Citation
  • 240

    Lonning PE, Bajetta E, Murray R et al. . Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:22342244.

    • Search Google Scholar
    • Export Citation
  • 241

    Dombernowsky P, Smith I, Falkson G et al. . Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453461.

    • Search Google Scholar
    • Export Citation
  • 242

    Buzdar A, Jonat W, Howell A et al. . Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:20002011.

    • Search Google Scholar
    • Export Citation
  • 243

    Carrick S, Parker S, Wilcken N et al. . Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372.

    • Search Google Scholar
    • Export Citation
  • 244

    Sledge GW, Neuberg D, Bernardo P et al. . Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588592.

    • Search Google Scholar
    • Export Citation
  • 245

    O’Shaughnessy J, Miles D, Vukelja S et al. . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:28122823.

    • Search Google Scholar
    • Export Citation
  • 246

    Albain K, Nag S, Calderillo-Ruiz J et al. . Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol 2004;22:14s(Suppl 1):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 247

    Muss HB, Case LD, Richards F II et al. . Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991:325;13421348.

    • Search Google Scholar
    • Export Citation
  • 248

    Falkson G, Gelman R, Pandya K et al. . Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:16691676.

    • Search Google Scholar
    • Export Citation
  • 249

    Miller KD, Wang M, Gralow J et al. . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:26662676.

    • Search Google Scholar
    • Export Citation
  • 250

    Roche H, Yelle L, Cognetti F et al. . Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:34153420.

    • Search Google Scholar
    • Export Citation
  • 251

    Thomas E, Tabernero J, Fornier M et al. . Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:33993406.

    • Search Google Scholar
    • Export Citation
  • 252

    Perez EA, Lerzo G, Pivot X et al. . Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:34073414.

    • Search Google Scholar
    • Export Citation
  • 253

    Thomas ES, Gomez HL, Li RK et al. . Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:52105217.

    • Search Google Scholar
    • Export Citation
  • 254

    Seidman AD, Berry D, Cirrincione C et al. . Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol 2008;26:16421649.

    • Search Google Scholar
    • Export Citation
  • 255

    Roche PC, Suman VJ, Jenkins RB et al. . Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94:855857.

    • Search Google Scholar
    • Export Citation
  • 256

    Robert N, Leyland-Jones B, Asmar K et al. . Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:27862792.

    • Search Google Scholar
    • Export Citation
  • 257

    Burstein HJ, Keshaviah A, Baron AD et al. . Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965972.

    • Search Google Scholar
    • Export Citation
  • 258

    Yamamoto D, Iwase S, Kitamura K et al. . A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol 2008;61:509514.

    • Search Google Scholar
    • Export Citation
  • 259

    Schaller G, Bangemann N, Weber J et al. . Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol 2005;23:18(Suppl 1):Abstract 717.

    • Search Google Scholar
    • Export Citation
  • 260

    Seidman A, Hudis C, Pierri MK et al. . Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:12151221.

  • 261

    Bartsch R, Wenzel C, Altorjai G et al. . Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:38533858.

    • Search Google Scholar
    • Export Citation
  • 262

    Von Minckwitz G, Vogel P, Schmidt M et al. . Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—interim report [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4056.

    • Search Google Scholar
    • Export Citation
  • 263

    Von Minckwitz G, Zielinski C, Maarteense E et al. . Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1025.

    • Search Google Scholar
    • Export Citation
  • 264

    Geyer CE, Forster J, Lindquist D et al. . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:27332743.

  • 265

    O’Shaughnessy J, Blackwell KL, Burstein H et al. . A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1015.

    • Search Google Scholar
    • Export Citation
  • 266

    Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416423.

  • 267

    Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620627.

  • 268

    Babiera GV, Rao R, Feng L et al. . Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776782.

    • Search Google Scholar
    • Export Citation
  • 269

    Rapiti E, Verkooijen HM, Vlastos G et al. . Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:27432749.

    • Search Google Scholar
    • Export Citation
  • 270

    Rao R, Feng L, Kuerer HM et al. . Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008;15:16961702.

    • Search Google Scholar
    • Export Citation
  • 271

    Morrow M, Goldstein LJ. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol 2006;24:26942696.

    • Search Google Scholar
    • Export Citation
  • 272

    Olson JA, Marcom PK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg 2008;247:739740.

    • Search Google Scholar
    • Export Citation
  • 273

    Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:10141024.